108-LB: Sustained Glucagon Effect on Blood Glucose and Improvements of Insulin Resistance Mediated by a Novel Long-Acting Glucagon Analog, HM15136, in Animal Models

HM15136 is a novel long-acting glucagon (GCG) analog conjugated with human IgG FC fragment via a short PEG linker. Previously, HM15136 treatment led to body weight loss (BWL) in obese animal models while showing transient effect on blood glucose (BG). Insulin resistance (IR) can lead to imbalances i...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Diabetes (New York, N.Y.) N.Y.), 2019-06, Vol.68 (Supplement_1)
Hauptverfasser: CHOI, JAEHYUK, LEE, SEON MYEONG, KIM, JUNG KUK, LEE, JONGSOO, KIM, YOUNG HOON, CHOI, IN YOUNG
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue Supplement_1
container_start_page
container_title Diabetes (New York, N.Y.)
container_volume 68
creator CHOI, JAEHYUK
LEE, SEON MYEONG
KIM, JUNG KUK
LEE, JONGSOO
KIM, YOUNG HOON
CHOI, IN YOUNG
description HM15136 is a novel long-acting glucagon (GCG) analog conjugated with human IgG FC fragment via a short PEG linker. Previously, HM15136 treatment led to body weight loss (BWL) in obese animal models while showing transient effect on blood glucose (BG). Insulin resistance (IR) can lead to imbalances in BG homeostasis in obesity, representing a key risk factor for T2DM. Considering the potential benefit of BWL in IR improvement, HM15136 could be a novel therapeutic option for obesity treatment. To assess this concept, the present study evaluated the effect of HM15136 on BG as well as BW, and investigated the mechanism leading to IR improvement in vitro and in vivo. In DIO rats, 4 weeks treatment of HM15136 led to remarkable BWL (-17 ∼ -42% vs. Veh). BG monitoring showed that an initial BG elevation was rapidly normalized and maintained normal thereafter, with no HbA1c increase (3.4 and 3.7% for Veh and HM15136). Similar results were also observed in DIO mice, showing no abnormal glycemic control by HM15136. Interestingly, BWL effect were correlated with free-fatty acid (FFA) and HOMA-IR reduction. In vitro studies in 3T3-L1 adipocytes further confirmed the deteriorating effect of FFA on insulin signaling. These results suggested that improvements in the lipotoxic milieu explains, at least in part, the IR improvement seen with HM15136. To further explore additional mechanism, inflammatory markers and adipokines affecting insulin signaling were evaluated. HM15136 not only inhibited F4/80 expression, but also increased FGF-21 and adiponectin expression in white adipose tissue and 3T3-L1 adipocytes. Our results demonstrated that BWL under by HM15136 therapy is accompanied by the reduction of 1) lipotoxicity, 2) inflammatory biomarkers, and the expression of 3) insulin-sensitizing adipokines, eventually leading to IR reversal and normal BG maintenance. Human studies are needed to confirm whether these findings will translate into humans.
doi_str_mv 10.2337/db19-108-LB
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2248402577</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2248402577</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1067-97751aa1ed1456fa72e0b9d58e08690e0c206f7668982f442876a5571e1689413</originalsourceid><addsrcrecordid>eNpFUd9LwzAQDqLgnD75DwR81GiStknj2zbmNugU_AG-lay9lI4umU0r7P_xDzWjgtzD3X338d13HELXjN7zKJIP5YYpwmhKsukJGjEVKRJx-XmKRpQyTphU8hxdeL-llIoQI_QzsB_xW-87XVso8aLpC105i-fGQNHhUE0b54aB84C1LfFqt2_dN-zAdh47g1fW901t8Sv4OgjZAvAaylp3QXBzwBo_B3aDM2crMim62lb_eyZWN666w8s1S1gk7nB9xOqdbvDaldD4S3RmdOPh6i-P0cfT_H22JNnLYjWbZKRgVEiipEyY1gxKFifCaMmBblSZpEBToSjQglNhpBCpSrmJY55KoZNEMmABilk0RjeDbrjtqwff5VvXt8GdzzmP05jyRMrAuh1YReu8b8Hk-zaYbQ85o_nxDfnxDaFJ82wa_QJsaHgH</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2248402577</pqid></control><display><type>article</type><title>108-LB: Sustained Glucagon Effect on Blood Glucose and Improvements of Insulin Resistance Mediated by a Novel Long-Acting Glucagon Analog, HM15136, in Animal Models</title><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>CHOI, JAEHYUK ; LEE, SEON MYEONG ; KIM, JUNG KUK ; LEE, JONGSOO ; KIM, YOUNG HOON ; CHOI, IN YOUNG</creator><creatorcontrib>CHOI, JAEHYUK ; LEE, SEON MYEONG ; KIM, JUNG KUK ; LEE, JONGSOO ; KIM, YOUNG HOON ; CHOI, IN YOUNG</creatorcontrib><description>HM15136 is a novel long-acting glucagon (GCG) analog conjugated with human IgG FC fragment via a short PEG linker. Previously, HM15136 treatment led to body weight loss (BWL) in obese animal models while showing transient effect on blood glucose (BG). Insulin resistance (IR) can lead to imbalances in BG homeostasis in obesity, representing a key risk factor for T2DM. Considering the potential benefit of BWL in IR improvement, HM15136 could be a novel therapeutic option for obesity treatment. To assess this concept, the present study evaluated the effect of HM15136 on BG as well as BW, and investigated the mechanism leading to IR improvement in vitro and in vivo. In DIO rats, 4 weeks treatment of HM15136 led to remarkable BWL (-17 ∼ -42% vs. Veh). BG monitoring showed that an initial BG elevation was rapidly normalized and maintained normal thereafter, with no HbA1c increase (3.4 and 3.7% for Veh and HM15136). Similar results were also observed in DIO mice, showing no abnormal glycemic control by HM15136. Interestingly, BWL effect were correlated with free-fatty acid (FFA) and HOMA-IR reduction. In vitro studies in 3T3-L1 adipocytes further confirmed the deteriorating effect of FFA on insulin signaling. These results suggested that improvements in the lipotoxic milieu explains, at least in part, the IR improvement seen with HM15136. To further explore additional mechanism, inflammatory markers and adipokines affecting insulin signaling were evaluated. HM15136 not only inhibited F4/80 expression, but also increased FGF-21 and adiponectin expression in white adipose tissue and 3T3-L1 adipocytes. Our results demonstrated that BWL under by HM15136 therapy is accompanied by the reduction of 1) lipotoxicity, 2) inflammatory biomarkers, and the expression of 3) insulin-sensitizing adipokines, eventually leading to IR reversal and normal BG maintenance. Human studies are needed to confirm whether these findings will translate into humans.</description><identifier>ISSN: 0012-1797</identifier><identifier>EISSN: 1939-327X</identifier><identifier>DOI: 10.2337/db19-108-LB</identifier><language>eng</language><publisher>New York: American Diabetes Association</publisher><subject>Adipocytes ; Adiponectin ; Adipose tissue ; Animal models ; Blood glucose ; Body weight ; Body weight loss ; Fibroblast growth factors ; Glucagon ; Glucose monitoring ; Homeostasis ; Immunoglobulin G ; Inflammation ; Insulin ; Insulin resistance ; Obesity ; Risk factors ; Weight control</subject><ispartof>Diabetes (New York, N.Y.), 2019-06, Vol.68 (Supplement_1)</ispartof><rights>Copyright American Diabetes Association Jun 1, 2019</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1067-97751aa1ed1456fa72e0b9d58e08690e0c206f7668982f442876a5571e1689413</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>CHOI, JAEHYUK</creatorcontrib><creatorcontrib>LEE, SEON MYEONG</creatorcontrib><creatorcontrib>KIM, JUNG KUK</creatorcontrib><creatorcontrib>LEE, JONGSOO</creatorcontrib><creatorcontrib>KIM, YOUNG HOON</creatorcontrib><creatorcontrib>CHOI, IN YOUNG</creatorcontrib><title>108-LB: Sustained Glucagon Effect on Blood Glucose and Improvements of Insulin Resistance Mediated by a Novel Long-Acting Glucagon Analog, HM15136, in Animal Models</title><title>Diabetes (New York, N.Y.)</title><description>HM15136 is a novel long-acting glucagon (GCG) analog conjugated with human IgG FC fragment via a short PEG linker. Previously, HM15136 treatment led to body weight loss (BWL) in obese animal models while showing transient effect on blood glucose (BG). Insulin resistance (IR) can lead to imbalances in BG homeostasis in obesity, representing a key risk factor for T2DM. Considering the potential benefit of BWL in IR improvement, HM15136 could be a novel therapeutic option for obesity treatment. To assess this concept, the present study evaluated the effect of HM15136 on BG as well as BW, and investigated the mechanism leading to IR improvement in vitro and in vivo. In DIO rats, 4 weeks treatment of HM15136 led to remarkable BWL (-17 ∼ -42% vs. Veh). BG monitoring showed that an initial BG elevation was rapidly normalized and maintained normal thereafter, with no HbA1c increase (3.4 and 3.7% for Veh and HM15136). Similar results were also observed in DIO mice, showing no abnormal glycemic control by HM15136. Interestingly, BWL effect were correlated with free-fatty acid (FFA) and HOMA-IR reduction. In vitro studies in 3T3-L1 adipocytes further confirmed the deteriorating effect of FFA on insulin signaling. These results suggested that improvements in the lipotoxic milieu explains, at least in part, the IR improvement seen with HM15136. To further explore additional mechanism, inflammatory markers and adipokines affecting insulin signaling were evaluated. HM15136 not only inhibited F4/80 expression, but also increased FGF-21 and adiponectin expression in white adipose tissue and 3T3-L1 adipocytes. Our results demonstrated that BWL under by HM15136 therapy is accompanied by the reduction of 1) lipotoxicity, 2) inflammatory biomarkers, and the expression of 3) insulin-sensitizing adipokines, eventually leading to IR reversal and normal BG maintenance. Human studies are needed to confirm whether these findings will translate into humans.</description><subject>Adipocytes</subject><subject>Adiponectin</subject><subject>Adipose tissue</subject><subject>Animal models</subject><subject>Blood glucose</subject><subject>Body weight</subject><subject>Body weight loss</subject><subject>Fibroblast growth factors</subject><subject>Glucagon</subject><subject>Glucose monitoring</subject><subject>Homeostasis</subject><subject>Immunoglobulin G</subject><subject>Inflammation</subject><subject>Insulin</subject><subject>Insulin resistance</subject><subject>Obesity</subject><subject>Risk factors</subject><subject>Weight control</subject><issn>0012-1797</issn><issn>1939-327X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNpFUd9LwzAQDqLgnD75DwR81GiStknj2zbmNugU_AG-lay9lI4umU0r7P_xDzWjgtzD3X338d13HELXjN7zKJIP5YYpwmhKsukJGjEVKRJx-XmKRpQyTphU8hxdeL-llIoQI_QzsB_xW-87XVso8aLpC105i-fGQNHhUE0b54aB84C1LfFqt2_dN-zAdh47g1fW901t8Sv4OgjZAvAaylp3QXBzwBo_B3aDM2crMim62lb_eyZWN666w8s1S1gk7nB9xOqdbvDaldD4S3RmdOPh6i-P0cfT_H22JNnLYjWbZKRgVEiipEyY1gxKFifCaMmBblSZpEBToSjQglNhpBCpSrmJY55KoZNEMmABilk0RjeDbrjtqwff5VvXt8GdzzmP05jyRMrAuh1YReu8b8Hk-zaYbQ85o_nxDfnxDaFJ82wa_QJsaHgH</recordid><startdate>20190601</startdate><enddate>20190601</enddate><creator>CHOI, JAEHYUK</creator><creator>LEE, SEON MYEONG</creator><creator>KIM, JUNG KUK</creator><creator>LEE, JONGSOO</creator><creator>KIM, YOUNG HOON</creator><creator>CHOI, IN YOUNG</creator><general>American Diabetes Association</general><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope></search><sort><creationdate>20190601</creationdate><title>108-LB: Sustained Glucagon Effect on Blood Glucose and Improvements of Insulin Resistance Mediated by a Novel Long-Acting Glucagon Analog, HM15136, in Animal Models</title><author>CHOI, JAEHYUK ; LEE, SEON MYEONG ; KIM, JUNG KUK ; LEE, JONGSOO ; KIM, YOUNG HOON ; CHOI, IN YOUNG</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1067-97751aa1ed1456fa72e0b9d58e08690e0c206f7668982f442876a5571e1689413</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adipocytes</topic><topic>Adiponectin</topic><topic>Adipose tissue</topic><topic>Animal models</topic><topic>Blood glucose</topic><topic>Body weight</topic><topic>Body weight loss</topic><topic>Fibroblast growth factors</topic><topic>Glucagon</topic><topic>Glucose monitoring</topic><topic>Homeostasis</topic><topic>Immunoglobulin G</topic><topic>Inflammation</topic><topic>Insulin</topic><topic>Insulin resistance</topic><topic>Obesity</topic><topic>Risk factors</topic><topic>Weight control</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>CHOI, JAEHYUK</creatorcontrib><creatorcontrib>LEE, SEON MYEONG</creatorcontrib><creatorcontrib>KIM, JUNG KUK</creatorcontrib><creatorcontrib>LEE, JONGSOO</creatorcontrib><creatorcontrib>KIM, YOUNG HOON</creatorcontrib><creatorcontrib>CHOI, IN YOUNG</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><jtitle>Diabetes (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>CHOI, JAEHYUK</au><au>LEE, SEON MYEONG</au><au>KIM, JUNG KUK</au><au>LEE, JONGSOO</au><au>KIM, YOUNG HOON</au><au>CHOI, IN YOUNG</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>108-LB: Sustained Glucagon Effect on Blood Glucose and Improvements of Insulin Resistance Mediated by a Novel Long-Acting Glucagon Analog, HM15136, in Animal Models</atitle><jtitle>Diabetes (New York, N.Y.)</jtitle><date>2019-06-01</date><risdate>2019</risdate><volume>68</volume><issue>Supplement_1</issue><issn>0012-1797</issn><eissn>1939-327X</eissn><abstract>HM15136 is a novel long-acting glucagon (GCG) analog conjugated with human IgG FC fragment via a short PEG linker. Previously, HM15136 treatment led to body weight loss (BWL) in obese animal models while showing transient effect on blood glucose (BG). Insulin resistance (IR) can lead to imbalances in BG homeostasis in obesity, representing a key risk factor for T2DM. Considering the potential benefit of BWL in IR improvement, HM15136 could be a novel therapeutic option for obesity treatment. To assess this concept, the present study evaluated the effect of HM15136 on BG as well as BW, and investigated the mechanism leading to IR improvement in vitro and in vivo. In DIO rats, 4 weeks treatment of HM15136 led to remarkable BWL (-17 ∼ -42% vs. Veh). BG monitoring showed that an initial BG elevation was rapidly normalized and maintained normal thereafter, with no HbA1c increase (3.4 and 3.7% for Veh and HM15136). Similar results were also observed in DIO mice, showing no abnormal glycemic control by HM15136. Interestingly, BWL effect were correlated with free-fatty acid (FFA) and HOMA-IR reduction. In vitro studies in 3T3-L1 adipocytes further confirmed the deteriorating effect of FFA on insulin signaling. These results suggested that improvements in the lipotoxic milieu explains, at least in part, the IR improvement seen with HM15136. To further explore additional mechanism, inflammatory markers and adipokines affecting insulin signaling were evaluated. HM15136 not only inhibited F4/80 expression, but also increased FGF-21 and adiponectin expression in white adipose tissue and 3T3-L1 adipocytes. Our results demonstrated that BWL under by HM15136 therapy is accompanied by the reduction of 1) lipotoxicity, 2) inflammatory biomarkers, and the expression of 3) insulin-sensitizing adipokines, eventually leading to IR reversal and normal BG maintenance. Human studies are needed to confirm whether these findings will translate into humans.</abstract><cop>New York</cop><pub>American Diabetes Association</pub><doi>10.2337/db19-108-LB</doi></addata></record>
fulltext fulltext
identifier ISSN: 0012-1797
ispartof Diabetes (New York, N.Y.), 2019-06, Vol.68 (Supplement_1)
issn 0012-1797
1939-327X
language eng
recordid cdi_proquest_journals_2248402577
source EZB-FREE-00999 freely available EZB journals; PubMed Central
subjects Adipocytes
Adiponectin
Adipose tissue
Animal models
Blood glucose
Body weight
Body weight loss
Fibroblast growth factors
Glucagon
Glucose monitoring
Homeostasis
Immunoglobulin G
Inflammation
Insulin
Insulin resistance
Obesity
Risk factors
Weight control
title 108-LB: Sustained Glucagon Effect on Blood Glucose and Improvements of Insulin Resistance Mediated by a Novel Long-Acting Glucagon Analog, HM15136, in Animal Models
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T00%3A50%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=108-LB:%20Sustained%20Glucagon%20Effect%20on%20Blood%20Glucose%20and%20Improvements%20of%20Insulin%20Resistance%20Mediated%20by%20a%20Novel%20Long-Acting%20Glucagon%20Analog,%20HM15136,%20in%20Animal%20Models&rft.jtitle=Diabetes%20(New%20York,%20N.Y.)&rft.au=CHOI,%20JAEHYUK&rft.date=2019-06-01&rft.volume=68&rft.issue=Supplement_1&rft.issn=0012-1797&rft.eissn=1939-327X&rft_id=info:doi/10.2337/db19-108-LB&rft_dat=%3Cproquest_cross%3E2248402577%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2248402577&rft_id=info:pmid/&rfr_iscdi=true